Volume : 11, Issue : 01, January – 2024
Title:
A REVIEW ARTICLE ON TRIAMTERENE DRUG – DIURETIC
Authors :
M.Varalakshmi*, R.Jona Methusala
Abstract :
Triamterene is a potassium-sparing diuretic that has been in use since 1964. Triamterene is used by physicians who treat patients with fluid retention states secondary to conditions such as congestive heart failure, nephrotic kidney disease, liver cirrhosis, secondary hyperaldosteronism, or even merely idiopathic edema; all of which are FDA approved indications. When giving Triamterene in the combination dosage form with hydrochlorothiazide, other FDA-approved indications of use include the management of hypertension or the treatment of edema in patients who develop hypokalemia secondary to hydrochlorothiazide monotherapy. Of note, the use of Triamterene can also be indicated for overcoming diuretic resistance in patients on only one full dose of a diuretic; by combining two types of diuretics such as Triamterene with a loop diuretic, a diuretic synergism would successfully overcome the resistance and achieve the desired reduction in edema.
Triamterene (TA) is a mild ‘potassium-sparing’ diuretic usually employed in combination with other more potent diuretics in the treatment of hypertension. TA pharmacokinetics and pharmacodynamics in normal volunteers, elderly subjects and in patients with renal and hepatic dysfunction are reviewed. A variety of adverse renal effects, such as abnormalities in urinary sediment, nephrolithiasis, interstitial nephritis and acute renal failure, has been reported to occur and is also reviewed. Of particular concern with the increased availability of ‘over-the-counter’ nonsteroidal anti-inflammatory medications (NSAID) is the adverse interaction between TA and NSAID which may culminate in acute renal failure. Although a rare occurrence, the clinician should be aware of potential adverse reactions associated with the use of TA.
Cite This Article:
Please cite this article in press M.Varalakshmi et al., A Review Article On Triamterene Drug – Diuretic, Indo Am. J. P. Sci, 2024; 11 (01).
Number of Downloads : 10
References:
1. Chakravarty R, Samanta K, Mandal P, Karmakar S. Mechanism of action of diuretic and anti-diuretic drugs. In How Synthetic Drugs Work 2023 Jan 1 (pp. 369-390). Academic Press.
2. Li Y, Cheng KC, Niu CS, Lo SH, Cheng JT, Niu HS. Investigation of triamterene as an inhibitor of the TGR5 receptor: Identification in cells and animals. Drug design, development and therapy. 2017 Apr 5:1127-34.
3. Guillotin D, Austin P, Begum R, Freitas MO, Merve A, Brend T, Short S, Marino S, Martin SA. Drug-repositioning screens identify Triamterene as a selective drug for the treatment of DNA Mismatch Repair deficient cells. Clinical Cancer Research. 2017 Jun 1; 23(11):2880-90.
4. Fiori J, Ballardini R, Andrisano V, Cavrini V. Photostability studies on the furosemide–triamterene drug association. IL farmaco. 2003 Sep 1; 58(9):867-73.
5. Sica DA, Gehr TW. Triamterene and the kidney. Nephron. 1989 Dec 9; 51(4):454-61.
6. Gilfrich HJ, Kremer G, Möhrke W, Mutschler E, Völger KD. Pharmacokinetics of triamterene after iv administration to man: determination of bioavailability. European journal of clinical pharmacology. 1983 Aug; 25:237-41.
7. Gines JM, Arias MJ, Holgado MA, Arevalo MF, Rabasco AM. Dissolution rate study of fresh and aging triamterene-urea solid dispersions. Drug development and industrial pharmacy. 1994 Jan 1; 20(17):2729-40.
8. Hip UT. L ong-term use of the photosensitizing antihypertensive drugs, hydro-chlorothiazide, combined hydrochlorothiazide-triamterene, and nifed. ARCH INTERN MED. 2012 Sep 10; 172(16).
9. Darken M, McBurney EI. Subcutaneous lupus erythematosus-like drug eruption due to combination diuretic hydrochlorothiazide and triamterene. Journal of the American Academy of Dermatology. 1988 Jan 1; 18(1 Pt 1):38-42.
10. Vargas F, Fuentes A, Sequera J, Méndez H, Fraile G, Velásquez M, Medina R. In Vitro Approach to investigating the phototoxicity of the diuretic drug triamterene. Toxicology in vitro. 1998 Dec 1; 12(6):661-7.